Singapore Institute of Advanced Medicine's (SGX:9G2) attributable loss to equity holders from continuing operations narrowed to SG$6.6 million during the fiscal fourth quarter ended June 30 from SG$8.2 million a year earlier, according to a Saturday filing.
Loss per share came in at SG$0.0052 compared with SG$0.0077 in the year-ago period.
Revenue was relatively unchanged at SG$3.7 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.